Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the ‘NEXT-IN-CML' Study

Small retrospective studies have suggested that NGS may have several advantages over Sanger sequencing for BCR-ABL1 KD domain mutation screening in Ph+ leukemia patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Leukemia | Lymphoma | Myeloma | Study